Latest News and Press Releases

Austin, TX, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Injectable Drug Delivery Devices Market Size, Trends and Insights By Device Type...

Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.

Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.

Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.

Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...

CEPI to initially provide up to US$1.6 million to aVaxziPen to advance development of needle-free vaccine technology aVaxziPen’s innovative vaccine delivery platform aims to improve access to...

OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World...

CLEVELAND, July 18, 2018 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to provide high-quality, patient-centered medical care, University Hospitals (UH) today announced that it has...

TOKYO, June 13, 2016 (GLOBE NEWSWIRE) -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that the Phase 3 clinical trial on “SyB P-1501” – a drug for...